PRESCRIPTION ANALYSIS OF HYPERTENSIVE PATIENTS AND AWARENESS AMONG PHYSICIAN REGARDING ANTIHYPERTENSIVE DRUG

Authors

  • PATIL P. J. Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune 411033
  • PATIL V. S. Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune 411033
  • BHORE P. Marathwada Mitra Mandal’s College of Pharmacy, Thergaon, Pune 411033

DOI:

https://doi.org/10.22159/ijcpr.2020v12i2.27521

Keywords:

Rational use of Drugs, Survey on antihypertensive use, Awareness, Knowledge regarding combination drug use hypertensive patient

Abstract

Objective: This study was conducted to analyze prescriptions of the hypertensive patient and to determine the awareness of physicians regarding antihypertensive drugs.

Methods: Prepare a questionnaire by the pilot study on five physicians. Review and finalized the questionnaire after discussion with pharmacologist. The answers were seek for awareness. Moreover the prescription of 30 patients was collected from the same physician who has undertaken the awareness regarding Antihypertensive Drugs. Study was conducted during Oct-2019 to Dec 2019.

Results: Average 83% awareness was found in the physician regarding antihypertensive drugs. Lack of awareness regarding diabetes and in ulcer patients was observed. Highest drug is given i.e. β blockers in antihypertensive patients. To determine the irrationality in the prescription of hypertensive patients.

Conclusion: To determine the FDC`s given to hypertensive patients. To determine the type of antihypertensive drugs given to patients.

Downloads

Download data is not yet available.

References

1. Puoane T, Tsolekile L, Sanders D, Parker W. Chronic non-communicable diseases. In: Barron P, Roma Reardon J. eds. South African Health Review. Durban: Health Systems Trust; 2008. p. 73-87.
2. Strong K, Mathers C, Leeder S, Beaglehole R. Preventing chronic diseases: how many lives can we save? Lancet 2005;366:1578-82.
3. Habib SH, Soma S. Burden of non-communicable disease: global overview. diabetes and metabolic syndrome. Clin Res Rev 2010;4:41-7.
4. Brown MJ, Haydock S. Pathoaetiology, epidemiology and diagnosis of hypertension. Drugs 2000;59 Suppl 2:1-12.
5. Guilbert JJ. The world health report 2002-reducing risks, promoting healthy life. Educ Health (Abingdon) 2003;16:230.
6. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.
7. Hypertension Study G. Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: a multicentre study. Bull World Health Organ 2001;79:490-500.
8. Nissinen A, Bothig S, Granroth H, Lopez AD. Hypertension in developing countries. World Health Stat Q 1988;41:141-54.
9. David Rodrigues, Drug-drug interaction. 2nd edition. Vol. 179. Stockley’s Drug Interactions, Edited by Karen Baxter; 2009.
10. Hand book of Food drug interactions, Edited by Beverly J. McCabe Eric H. Frankel, Jonathan J. Wolfe CRC Press; 2003.
11. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admissio to hospital: prospective analysis of 18 820 patients. Br Med J 2004;329:15-9.
12. Royal S, Smeaton L, Avery AJ. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Qual Saf Health Care 2006;15:23-31.
13. Rupp MT, DeYoung M, Schondelmeyer SW. Prescribing problems and pharmacist interventions in community practice. Med Care 1992;30:926-40.
14. Leemans L, Veroeveren L, Bulens J, Hendrickx C, Keyenberg W, Niesten F, et al. Frequency and trends of intervention of prescriptions in flemish community pharmacies. Pharm World Sci 2003;25:65-9.
15. Hong CY, Hu SC, Lin SJ. Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol. Int J Clin Pharmacol Ther Toxicol 1985;23:244–6.

Published

15-03-2020

How to Cite

J., P. P., P. V. S., and B. P. “PRESCRIPTION ANALYSIS OF HYPERTENSIVE PATIENTS AND AWARENESS AMONG PHYSICIAN REGARDING ANTIHYPERTENSIVE DRUG”. International Journal of Current Pharmaceutical Research, vol. 12, no. 2, Mar. 2020, pp. 124-8, doi:10.22159/ijcpr.2020v12i2.27521.

Issue

Section

Original Article(s)